Captisol-enabled® Sertraline (LGD-953) is designed to be the potential first aqueous oral solution to meet the growing demand for better liquid antidepressants for elderly and pediatric patients who are the least able to ingest pills. LGD-953 is designed for direct administration of the sertraline dose using a teaspoon or unit dose container which eliminates the dilution step required to dose the currently available commercial product. LGD-953 is designed as an all aqueous-based formulation containing no alcohol, which provides for improved taste and stability. A pilot pharmacokinetic study has been successfully completed and a formulation has been finalized.
